Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
Benitec Biopharma Inc. filed a Form 8-K under Item 4.01 regarding a change in its independent registered public accounting firm. The Audit Committee dismissed Baker Tilly US, LLP on September 18, 2026 and notified Baker Tilly on September 21, 2026. The report was signed and dated September 24, 2026. The company’s fiscal year ends June 30.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other current financial metrics. It states that Baker Tilly’s audit reports for the fiscal years ended June 30, 2026 and June 30, 2025 contained no adverse opinion, disclaimer, going-concern qualification, or qualification relating to audit scope or accounting principles.
Material Changes Versus the Prior Comparable Period
- Baker Tilly, the company’s auditor since 2020, was dismissed following a review of the independent audit engagement.
- Ernst & Young LLP was appointed as auditor for the fiscal year ending June 30, 2027, subject to completion of EY’s client acceptance process.
- The company reported no disagreements with Baker Tilly regarding accounting principles, financial statement disclosure, or audit scope or procedures during fiscal 2025, fiscal 2026, or the subsequent period through September 21, 2026.
- A previously reported material weakness involving the design and implementation of controls over share-based compensation calculation review was remediated as of June 30, 2026.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing provides no financial guidance or operating outlook. The principal accounting-related matter disclosed is the previously reported material weakness in internal control over financial reporting, which management reported as remediated as of June 30, 2026. Baker Tilly was authorized to respond to EY’s inquiries regarding that matter.
The company stated that neither it nor anyone acting on its behalf consulted EY about specific accounting treatments, potential audit opinions, disagreements, or reportable events during the relevant periods. Baker Tilly’s September 24, 2026 letter is filed as Exhibit 16.1.
Important Facts for Investors to Verify
- Confirm completion of EY’s client acceptance process and its formal engagement for fiscal 2027.
- Review Exhibit 16.1 for Baker Tilly’s response to the company’s disclosures.
- Review the fiscal 2026 Form 10-K for details supporting remediation of the share-based compensation control weakness.
- Monitor future filings for any new internal-control deficiencies, audit disagreements, reportable events, or changes to the auditor appointment.